Antheia Lands $12M with Second BioMaP Deal to Reshape U.S. Pharma
The company was awarded for its ability to outperform conventional manufacturing methods for critical pharmaceutical ingredients and rapidly reach a commercial scale in the U.S.
Antheia Secures Second Project Agreement with the BioMaP-Consortium Valued at up to $12M
Company awarded for its ability to outperform conventional manufacturing methods for critical pharmaceutical ingredients and rapidly reach commercial scale in the U.S.